A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Completed · Phase 4

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.

Key facts

Study ID

NCT00240253

Run by

AstraZeneca

People needed

200

Starts

2005-10-01

Expected to finish

2006-06-01

Last updated by the study team

2015-03-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has HbA1c >7.0% and <=10.5%
• Has a body mass index (BMI) >=25 kg/m2 and <=45 kg/m2
• Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start
• If taking oral antidiabetic agents, has been on a stable dose for at least 2 months

You may not qualify if…

• Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study)
• Has received any investigational drug within 1 month of screening

Where it is running

• Research Site — Phoenix, Arizona, United States
• Research Site — Concord, California, United States
• Research Site — La Jolla, California, United States
• Research Site — Los Gatos, California, United States
• Research Site — Salinas, California, United States
• Research Site — Walnut Creek, California, United States
• Research Site — Denver, Colorado, United States
• Research Site — New Britain, Connecticut, United States
• Research Site — Washington D.C., District of Columbia, United States
• Research Site — Palm Harbor, Florida, United States
• Research Site — Atlanta, Georgia, United States
• Research Site — Indianapolis, Indiana, United States
• Research Site — Wichita, Kansas, United States
• Research Site — Lexington, Kentucky, United States
• Research Site — Baton Rouge, Louisiana, United States
• Research Site — Bloomfield Hills, Michigan, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Grand Rapids, Michigan, United States
• Research Site — Chesterfield, Missouri, United States
• Research Site — Butte, Montana, United States
• Research Site — Omaha, Nebraska, United States
• Research Site — Charlotte, North Carolina, United States
• Research Site — Durham, North Carolina, United States
• Research Site — Cincinnati, Ohio, United States
• Research Site — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.